Astra-Zeneca and Bristol-
Myers Squibb have announced that
Forxigar (dapagliflozin) tablets will
be listed on the PBS next month.
The first of a new class of therapy
called a selective and reversible
inhibitor of sodium-glucose
cotransporter 2 (SGLT2), Forxiga
works independently of insulin.
By selectively inhibiting SGLT2
in the kidneys, glucose and its
associated calories are excreted
in the urine enabling glycaemic
control.
The TGA’s approval of Forxiga
a year ago was the first time any
SGLT2 inhibitor had been registered
anywhere in the world, with the
pharmaceutical companies saying
they had “worked hard to bring this
therapy to patients and physicians
across Australia”.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Nov 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.